311 related articles for article (PubMed ID: 29730017)
1. Positron Emission Tomography/Computed Tomography with
Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
[TBL] [Abstract][Full Text] [Related]
2. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
3. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab.
van Oostenbrugge T; Mulders P
Curr Opin Urol; 2021 May; 31(3):249-254. PubMed ID: 33742975
[TBL] [Abstract][Full Text] [Related]
4. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
[TBL] [Abstract][Full Text] [Related]
6. Phase I study to assess safety, biodistribution and radiation dosimetry for
Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
[TBL] [Abstract][Full Text] [Related]
7. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
8. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with
van Oostenbrugge TJ; Langenhuijsen JF; Oosterwijk E; Boerman OC; Jenniskens SF; Oyen WJG; Fütterer JJ; Mulders PFA
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1864-1870. PubMed ID: 31768601
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
10. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
Verhoeff SR; Oosting SF; Elias SG; van Es SC; Gerritse SL; Angus L; Heskamp S; Desar IME; Menke-van der Houven van Oordt CW; van der Veldt AAM; Arens AIJ; Brouwers AH; Eisses B; Mulders PFA; Hoekstra OS; Zwezerijnen GJC; van der Graaf WTA; Aarntzen EHJG; Oyen WJG; van Herpen CML
Clin Cancer Res; 2023 Feb; 29(3):592-601. PubMed ID: 36394882
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Hekman MC; Rijpkema M; Muselaers CH; Oosterwijk E; Hulsbergen-Van de Kaa CA; Boerman OC; Oyen WJ; Langenhuijsen JF; Mulders PF
Theranostics; 2018; 8(8):2161-2170. PubMed ID: 29721070
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.
Divgi CR; Uzzo RG; Gatsonis C; Bartz R; Treutner S; Yu JQ; Chen D; Carrasquillo JA; Larson S; Bevan P; Russo P
J Clin Oncol; 2013 Jan; 31(2):187-94. PubMed ID: 23213092
[TBL] [Abstract][Full Text] [Related]
13. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
[TBL] [Abstract][Full Text] [Related]
14. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Hekman MC; Boerman OC; de Weijert M; Bos DL; Oosterwijk E; Langenhuijsen JF; Mulders PF; Rijpkema M
Clin Cancer Res; 2016 Sep; 22(18):4634-42. PubMed ID: 27103404
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
16. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Turkbey B; Lindenberg ML; Adler S; Kurdziel KA; McKinney YL; Weaver J; Vocke CD; Anver M; Bratslavsky G; Eclarinal P; Kwarteng G; Lin FI; Yaqub-Ogun N; Merino MJ; Linehan WM; Choyke PL; Metwalli AR
Abdom Radiol (NY); 2016 Jan; 41(1):109-18. PubMed ID: 26830617
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
19. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
